Misplaced Pages

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "EyePoint Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (March 2020) (Learn how and when to remove this message)

The topic of this article may not meet Misplaced Pages's notability guidelines for companies and organizations. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted. Find sources: "EyePoint Pharmaceuticals" – news · newspapers · books · scholar · JSTOR (November 2024) (Learn how and when to remove this message)

EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.

pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency (DERA, now QinetiQ). QinetiQ continues to be a strategic partner.

In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.

See also

• Alimera Sciences, pSvida's partner on Iluvien

References

1. ^ "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
2. "Nano silicon boosts tumour fight". 2004-06-18. Retrieved 2020-10-29.
3. "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
4. "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.
5. "pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company Will Rebrand as EyePoint Pharmaceuticals, Inc". EyePoint Pharmaceuticals. March 28, 2018. Retrieved March 28, 2018.

External links

• Official website
• "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
• Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015. pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon"
• pSivida Mesoporous silicon patent

v t e QinetiQ
Divisions and subsidiaries	Current Automatika Boldon James Cyveillance Foster-Miller Former Omni-ID
Shareholdings and partnerships	Defence Technology Centre Metrix UK PSivida
Products	Cerberus Foster-Miller TALON PyTEC QinetiQ 1 QinetiQ Banshee Q-Net QinetiQ Mercator QinetiQ Zephyr TopSat
Places and vessels	MoD Boscombe Down RAE Bedford RV Triton
Predecessors	Defence Evaluation and Research Agency Defence Research Agency ARE A&AEE MVEE RAE RARDE RSRE
People	John Chisholm Graham Love
Category

This United States manufacturing company–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Qinetiq
• Nanotechnology companies
• Companies based in Middlesex County, Massachusetts
• Drug delivery devices
• Pharmaceutical companies of the United States
• Health care companies based in Massachusetts
• United States manufacturing company stubs
• Medical company stubs